Novel applications of molecular imaging to guide breast cancer therapy
Open Access
- 21 June 2022
- journal article
- review article
- Published by Springer Nature in Cancer Imaging
- Vol. 22 (1) , 1-17
Abstract
The goals of precision oncology are to provide targeted drug therapy based on each individual’s specific tumor biology, and to enable the prediction and early assessment of treatment response to allow treatment modification when necessary. Thus, precision oncology aims to maximize treatment success while minimizing the side effects of inadequate or suboptimal therapies. Molecular imaging, through noninvasive assessment of clinically relevant tumor biomarkers across the entire disease burden, has the potential to revolutionize clinical oncology, including breast oncology. In this article, we review breast cancer positron emission tomography (PET) imaging biomarkers for providing early response assessment and predicting treatment outcomes. For 2-18fluoro-2-deoxy-D-glucose (FDG), a marker of cellular glucose metabolism that is well established for staging multiple types of malignancies including breast cancer, we highlight novel applications for early response assessment. We then review current and future applications of novel PET biomarkers for imaging the steroid receptors, including the estrogen and progesterone receptors, the HER2 receptor, cellular proliferation, and amino acid metabolism.Keywords
This publication has 150 references indexed in Scilit:
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studiesBMC Cancer, 2011
- Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast CancerClinical Cancer Research, 2011
- Molecular imaging of HER2-positive breast cancer: a step toward an individualized ‘image and treat’ strategyCurrent Opinion in Oncology, 2010
- Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast CancerClinical Cancer Research, 2010
- The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniquesEuropean Journal of Surgical Oncology, 2010
- Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast CancerClinical Pharmacology & Therapeutics, 2010
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Cell proliferation in breast tumours: Analysis of histological parameters Ki67 and PCNA expressionIrish Journal of Medical Science (1971 -), 1993
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987